In conclusion, CML c-KITlo LT-HSCs showed reduced cell cycling signatures and increased STAT3 and NF-κB gene signatures, which are gene expression characteristics similar to those reported for BCR-ABL+CD34+ cell subpopulations enriched in patients with CML following TKI treatment (38). This evidence concerns the gene NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive.